FlagInternationalUnited States


Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.

Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

Stock Quote
UPI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Financial Status IndicatorD
Change (%) Stock is Up 0.03 (1.90%)
Data as of 05/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
03/31/15Uroplasty and Vision-Sciences Complete Merger
Creates New Medical Device Company: Cogentix Medical, Inc. Cogentix shares will begin trading under symbol CGNT on April 1, 2015 MINNEAPOLIS and ORANGEBURG, N.Y., March 31, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) today announced the completion of their merger. The merger was originally announced in December 2014, and completion of the all-stock combination creates a new medical device company named Cogentix Medical, Inc. Beginning on Ap... 
 Printer Friendly Version
03/30/15Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
MINNEAPOLIS and ORANGEBURG, N.Y., March 30, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies. "We are pleased with the outcome of today's special meetings, and I would like to thank both shareholder groups for approving the merger agreement," said Rob Kill, President and CE... 
 Printer Friendly Version
03/03/15Uroplasty to Host Investor Meeting at Corporate Headquarters
March 12th Event to Feature Urologist Perspective on the Use of Uroplasty and Vision-Sciences Product Lines MINNEAPOLIS, March 3, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty's corporate headquarters in Minnetonka, Minnesota.     ... 
 Printer Friendly Version
02/27/15Uroplasty to Participate in the 27th Annual ROTH Conference
MINNEAPOLIS, Feb. 27, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that it will participate in the 27th Annual ROTH Conference on Tuesday, March 10, 2015. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 4:00 p.m. Pacific Time and meet with investors one on one at the conference at the Ritz Carlton in Lagun... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Uroplasty, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.